This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Oh, D.-Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. https://doi.org/10.1016/S2468-1253(22)00043-7 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study. Nat Rev Gastroenterol Hepatol 19, 280 (2022). https://doi.org/10.1038/s41575-022-00616-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00616-8